Nasdaq

Ascendis Pharma's sBLA for TransCon hGH in Adult Growth Hormone Deficiency Accepted by FDA for Review

Ascendis Pharma's supplemental application for SKYTROFA in adult GHD has been accepted by the FDA, aiming for broader patient access. Acceptance of the sBLA does not guarantee approval; the company ...
ksn.com

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, ...
WebMD

Does Human Growth Hormone Affect Alzheimer's Risk?

Recent research findings put a spotlight on the link between human growth hormone (HGH) and Alzheimer’s disease. Could taking HGH increase your risk of Alzheimer’s? Ultimately, scientists say they ...
WebMD

Skytrofa Approved as Once-Weekly Option for Adults With Growth Hormone Deficiency

What Is Skytrofa, and Why Does It Matter? Skytrofa (lonapegsomatropin-tcgd) is a long-acting version of human growth hormone (hGH). It is already approved for children with growth hormone deficiency ...
Nasdaq

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug ...
ksn.com

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial ...